Delving into the Latest Updates on Anti-CD19 CAR-T cell therapy(Fujian Medical University) with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms-

Target

CD19

Action

inhibitors

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Gene transference(Gene transference)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

B-cell lymphoma recurrentB-cell lymphoma refractoryCD19 positive Acute Lymphoblastic Leukemia+ [1]

Originator Organization

Fujian Medical University

Active Organization-

Inactive Organization

Fujian Medical University

License Organization-

Drug Highest PhasePendingPhase 2/3

First Approval Date-

Regulation-

Login to view timeline

CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.

Start Date01 Nov 2016

Sponsor / Collaborator

Fujian Medical University

NCT03391739

/ Unknown statusPhase 2/3IIT

CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.

Start Date01 Jan 2016

Sponsor / Collaborator

Fujian Medical University

NCT03391726

/ Unknown statusPhase 2/3IIT

CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma

Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.

Start Date01 Jan 2016

Sponsor / Collaborator

Fujian Medical University

100 Clinical Results associated with Anti-CD19 CAR-T cell therapy(Fujian Medical University)

Login to view more data

100 Translational Medicine associated with Anti-CD19 CAR-T cell therapy(Fujian Medical University)

Login to view more data

100 Patents (Medical) associated with Anti-CD19 CAR-T cell therapy(Fujian Medical University)

Login to view more data

100 Deals associated with Anti-CD19 CAR-T cell therapy(Fujian Medical University)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CD19 positive Acute Lymphoblastic Leukemia	Phase 3	China	Fujian Medical University	01 Nov 2016
B-cell lymphoma recurrent	Phase 3	China	Fujian Medical University	01 Jan 2016
B-cell lymphoma refractory	Phase 3	China	Fujian Medical University	01 Jan 2016
Refractory B Acute Lymphoblastic Leukemia	Phase 3	China	Fujian Medical University	01 Jan 2016